Previous 10 | Next 10 |
2024-06-30 20:37:06 ET Summary Vanguard Total International Stock Index Fund ETF focuses on global companies with dividends. Reducing exposure to U.S. stocks and increasing exposure to global stocks could make sense right now. Top holdings include Taiwan Semiconductor, Novo No...
2024-06-30 20:30:56 ET Rounding out the top five were Moderna ( NASDAQ: MRNA ) and Novo Nordisk ( NVO ) with gains of, respectively, ~12.5% and ~11.9% .... Read the full article on Seeking Alpha For further details see: Alnylam, Lilly, AstraZeneca among best ...
2024-06-30 09:15:00 ET Novo Nordisk (NYSE: NVO) has emerged as one of the biggest names in the pharmaceutical world thanks to its robust line of glucagon-like peptide-1 (GLP-1) medicines. The Danish drugmaker develops Ozempic, Rybelsus, Saxenda, and Wegovy. While Ozempic is appr...
2024-06-29 15:44:55 ET More on Eli Lilly, Novo Nordisk, etc. Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Eli Lilly: Throwing Its Weight Around - But, For How Long? (Technical Analysis) Eli Lilly: The Party Is Probably Nearing The End ...
2024-06-29 11:34:00 ET For most of its existence, Altimmune (NASDAQ: ALT) has been a little-known biotech aspiring to compete in a world dominated by whales like Novo Nordisk (NYSE: NVO) , the maker of the hit weight loss drug Wegovy and the blockbuster Ozempic for type 2 di...
2024-06-27 16:48:49 ET Summary The small biotech sector has badly underperformed the major market indices so far in 2024. However, that could change as the Federal Reserve cuts interest rates and/or M&A deal volume picks up across the industry. Today, we highlight three sm...
2024-06-27 09:36:33 ET More on Hims & Hers Health Hims & Hers: Buy The Dip To Catch The Next Rip Hims & Hers: The Undervalued Gem Poised For Growth Hims & Hers: Compounded Semaglutide Boost Unlikely To Last - Moderate Risks Ahead Hims & He...
2024-06-27 07:56:37 ET Summary Ardelyx faces headwinds from emerging GLP-1 weight loss drugs, potentially reducing the patient pool for Xphozah. Recent increase in insider selling activity is notable and warrants attention. The company's high valuation looks unsustainable give...
2024-06-27 07:32:54 ET More on Novo Nordisk Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Novo Nordisk: Leading The Fight Against Diabetes And Obesity Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk buys 2seven...
2024-06-27 06:56:19 ET More on Novo Nordisk Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Novo Nordisk: Leading The Fight Against Diabetes And Obesity Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk hypertensio...
News, Short Squeeze, Breakout and More Instantly...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...
2024-07-13 17:52:00 ET Novo Nordisk (NYSE: NVO) is already a stock that's easy to justify buying. Between the incredible success of Ozempic, tons of demand for its weight loss medicine, and big investments in manufacturing as well as its pipeline, optimism about its future is practi...